A new study from the VITAL trial, published in The American Journal of Clinical Nutrition, reveals that vitamin D supplementation may slow biological ageing by preserving telomere length—the protective caps on chromosomes linked to cellular health.
Over a four-year period, more than 1,000 participants showed slower telomere shortening, suggesting vitamin D’s potential extended role in ageing and disease prevention.
Telomeres as a Biomarker in Cellular Ageing
Telomeres naturally shorten as individuals age, eventually leading cells into a non-dividing or apoptotic state, contributing to age-related decline.
“When telomeres become too short, cells enter senescence (a non-dividing state) or apoptosis (programmed cell death). Either condition of cell inactivity or death is thought to contribute to ageing and age-related diseases,” said Dr David Cutler, a family medicine physician at Providence Saint John’s Health Centre.
The new research set out to determine whether daily vitamin D and omega-3 supplementation could mitigate the pace of telomere shortening, potentially extending cellular lifespan.
Measurable Outcomes from Vitamin D Supplementation
The VITAL trial randomly assigned participants—women aged 55+ and men aged 50+—to receive vitamin D3, omega-3 fatty acids, both, or a placebo. Researchers measured telomere length in white blood cells (leukocytes) at baseline, two years, and four years.
The results demonstrated that vitamin D supplementation led to a significantly slower rate of telomere shortening compared to the placebo group. The effect was described by researchers as potentially equating to “a 3-year decrease in ageing.”
“As we know already, vitamin D supports bone, immune system and reduces inflammation, but this study is linked directly with telomere preservation which ties into ageing and disease prevention,” said Dr Yoshua Quinones. “
This study gives more of a general idea that vitamin D3 could do more than just helping your bones but actually slowing down the cellular age, impressive!”
Targeted Subgroup Findings Highlight Efficacy Variability
Subgroup analyses within the study found stronger vitamin D effects among non-white participants and individuals not on cholesterol medication. Those who were not obese also demonstrated greater protection against telomere shortening. Notably, omega-3 supplementation did not interfere with vitamin D’s observed benefits.
“If this is confirmed in future studies, this could mean that daily [vitamin D] supplements could actually help reduce risks for age-related diseases,” Quinones added. “This is a door for new medical guidelines in the future and will be a huge deal for preventive medicine.”
Study Limitations Highlight Need for Further Research
The study presented certain limitations, including missing data from 37% of participants by year four and limited cohort diversity—most participants were older and white. Additionally, as a post-hoc analysis, telomere preservation was not among the original endpoints of the VITAL trial.
Dr Cutler addressed these concerns: “The present study involved only a relatively small number of people, looked only at telomeres in white blood cells, and did not look extensively at the health impact of these telomere changes. So, the clinical implications one can derive from this study are quite limited.”
He also cautioned against over-supplementation: “While 2,000 units of vitamin D is unlikely to have any negative effects, there may be some risk… as they can cause kidney damage and other adverse effects in excessive quantities.”
The findings have opened new investigative avenues into how vitamin D may influence cellular ageing, including mechanisms such as telomerase activity and DNA repair. While public health guidelines remain unchanged, the data may inform future preventive medicine strategies and policy development.